CREB1 and ovarian serous cystadenocarcinoma: Evaluating The Cancer Genome Atlas (TCGA) data using the cBioPortal database36,37, showed only low numbers (with the exception of neuroendocrine prostate cancer: 12%) of genetic alterations for CREB1 (e.g. gene amplification) ranging from 1.3% in ccRCC to 5% in ovarian serous cystadenocarcinoma.